Compare Rockwell Automation (ROK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Sanofi SA — how do they compare? Rockwell Automation trades at $466.2 (market cap $51.04B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2.1× Rockwell Automation's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| ROK | SNY | |
|---|---|---|
Market Cap | $51.04B | $104.83B |
Sector | Industrials | Health |
52-Week High | $495.08 | $52.34 |
52-Week Low | $328.67 | $41.33 |
Enterprise Value | $54.67B | $121.32B |
Dividend Yield | 1.2% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $464.82, up 0.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 48.92% gross margin and 12.45% net margin, though valuation multiples like a 47.63 P/E appear elevated. Recent news highlights growth in industrial automation and AI infrastructure partnerships, including a contract with Aalo Atomics for nuclear reactor control systems (PRNewsWire, July 16, 2026).
Outlook is mixed: analyst consensus is a Buy with a $471.71 price target, but technical indicators suggest near-term pressure. Risks include margin compression and high debt levels, while opportunities lie in automation demand and new contracts. The stock offers a dividend yield of approximately 0.6% with consistent payouts.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
